Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed

STOCKHOLM, April 1, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: Leqembi®) intravenous (IV)…